Utility of XXXX fluorodeoxyglucose pos  tron em  ss  on tomography/computed   n carc  noma of unknown primary.

@entity5 @entity1 @entity29786 @entity189
@entity189 ( @entity189 ) is a heterogeneous group of @entity5 with various clinical features causing diagnostic and therapeutic challenges. The aim of this study was to evaluate the ability of @entity29786 FDG PET/CT for localizing the @entity5 , disclosing additional metastases, and changing the treatment in @entity1 with @entity189 . One hundred and twelve metastatic @entity1 (female = 40, male = 72, median age = 60.5 years) in whom conventional diagnostic work-up failed to disclose the @entity5 were included in the study. @entity29786 FDG PET/CT imaging was performed in a standard protocol ( @entity1 supine, arms on @entity1 's side, vertex to thigh, 369.3 MBq (296-444 MBq) @entity29786 FDG, a 60-minute uptake period, 6-7 bed position). Histopathology was taken as the only reference standard. @entity29786 FDG PET/CT correctly detected @entity5 in 37 of 112 (33.03%) @entity1 . The most common site of @entity5 detected by @entity29786 FDG PET/CT was lung (n = 18), which was followed by nasopharynx (n = 7), pancreas (n = 5), tonsil (n = 2), breast (n = 2), thyroid (n = 1), uterus (n = 1) and colon/rectum (n = 1). @entity29786 FDG PET/CT imaging disclosed additional previously undetected metastases in 32 (28.5%) and changed the treatment in 33 (29.4%) of 112 @entity1 . There were false positive @entity29786 FDG PET/CT results in 21 (18.5%) @entity1 . @entity29786 FDG PET/CT is able to disclose the @entity5 , disclose new metatases and change the treatment in about one third of @entity1 with @entity189 .
